What is the next available strength of Synthroid (levothyroxine) after 0.88 µg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Synthroid Dosage Strengths After 88 mcg

The next available strength of Synthroid after 88 mcg is 100 mcg. 1

Available Synthroid Strengths

According to the FDA-approved drug label, Synthroid (levothyroxine sodium) is available in the following tablet strengths 1:

  • 25 mcg
  • 50 mcg
  • 75 mcg
  • 88 mcg (current dose)
  • 100 mcg (next strength up)
  • 112 mcg
  • 125 mcg
  • 150 mcg
  • 175 mcg
  • 200 mcg
  • 300 mcg

Dose Adjustment Considerations

When adjusting levothyroxine doses, incremental changes of 12.5-25 mcg/day are typically made 2. The 88 mcg to 100 mcg transition represents a 12 mcg increase, which falls within the standard adjustment range.

Important Timing for Dose Changes

  • Wait 4-8 weeks after any dose adjustment before rechecking TSH levels, as this is the time required for TSH to plateau and reflect the new steady state 2
  • Smaller dose adjustments may require 8 weeks or longer before TSH levels stabilize 2

Clinical Context Matters

The decision to increase from 88 mcg to 100 mcg should be guided by:

  • Current TSH level (goal is normalization of TSH in primary hypothyroidism) 1
  • Clinical symptoms
  • Patient age and cardiovascular status
  • Body weight changes

Note: In elderly patients or those with cardiac disease, even smaller increments (12.5 mcg) may be preferable to the 12 mcg jump from 88 to 100 mcg, which could be achieved by alternating doses 1.

References

Guideline

clinical practice guidelines for hypothyroidism in adults: cosponsored by the american association of clinical endocrinologists and the american thyroid association.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.